Eric Bjerkholt Sells 5,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 5,000 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $93.82, for a total value of $469,100.00. Following the completion of the transaction, the chief financial officer owned 44,788 shares of the company’s stock, valued at $4,202,010.16. The trade was a 10.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, March 16th, Eric Bjerkholt sold 7,287 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $91.98, for a total value of $670,258.26.

Mirum Pharmaceuticals Trading Down 1.6%

Shares of Mirum Pharmaceuticals stock opened at $94.00 on Thursday. The firm has a market capitalization of $5.73 billion, a price-to-earnings ratio of -6.91 and a beta of 0.50. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $47.79 and a fifty-two week high of $114.99. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The stock has a 50 day moving average of $97.65 and a 200 day moving average of $90.87.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The business had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company’s revenue was up 43.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.30) earnings per share. As a group, research analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its stake in Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after purchasing an additional 880,505 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Mirum Pharmaceuticals by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock worth $205,065,000 after acquiring an additional 50,720 shares during the period. State Street Corp increased its position in shares of Mirum Pharmaceuticals by 59.2% during the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after acquiring an additional 797,088 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Mirum Pharmaceuticals by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock worth $112,196,000 after acquiring an additional 137,087 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of Mirum Pharmaceuticals by 56.6% during the fourth quarter. Wellington Management Group LLP now owns 1,237,830 shares of the company’s stock worth $97,776,000 after acquiring an additional 447,141 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. TD Cowen boosted their price target on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Royal Bank Of Canada upped their price target on Mirum Pharmaceuticals from $128.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Citizens Jmp restated a “market outperform” rating and set a $132.00 price target on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 21st. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday. Finally, Stifel Nicolaus set a $136.00 price target on Mirum Pharmaceuticals in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $137.64.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.